Zacks Investment Research on MSN2d
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagApellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Pharmaceutical Technology on MSN2d
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesApellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...
Sonida Senior Living's high debt and significant share dilution hinder its growth. See why we reiterate our hold rating on SNDA stock.
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Empaveli (pegcetacoplan) for two rare and severe kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback